ABSTRACT
The authors examined clinically and immunologically 60 patients with multiple sclerosis. One group (30 patients) received prednisolone in the complex treatment while the second group (30 patients) received only complex treatment. A control group of 20 healthy persons was examined. Patients of the first group showed marked neurological and immunological disorders which is considered as a complication due to the empiric prednisolone doses.
Subject(s)
Multiple Sclerosis/immunology , Prednisolone/administration & dosage , Antigen-Antibody Complex/blood , Central Nervous System Diseases/etiology , Central Nervous System Diseases/immunology , Chronic Disease , Combined Modality Therapy , Female , Humans , Immunoglobulins/blood , Immunoglobulins/drug effects , Male , Multiple Sclerosis/complications , Multiple Sclerosis/drug therapy , Prednisolone/adverse effectsABSTRACT
The authors examined the dynamics of IgA, IgM, IgG in the blood of 100 patients with multiple sclerosis. Of them 50 patients received complex treatment in combination with prednisolone. Comparison of indices of concentration of serum immunoglobulins revealed a distinct reduction of their level of all classes in patients with multiple sclerosis, especially in those receiving prednisolone. Prednisolone produced an unfavourable effect on the course of the demyelinating process in patients with multiple sclerosis.
Subject(s)
Immunoglobulins/analysis , Multiple Sclerosis/drug therapy , Prednisolone/therapeutic use , Adult , Antibody Formation/drug effects , Antibody Formation/immunology , Combined Modality Therapy , Humans , Multiple Sclerosis/immunology , Prednisolone/adverse effects , PrognosisSubject(s)
Multiple Sclerosis/diagnosis , Paresthesia/diagnosis , Sciatica/diagnosis , Arm , Diagnosis, Differential , Humans , Leg , Paresthesia/etiology , Sciatica/etiology , Time FactorsABSTRACT
To try to obviate the difficulties encountered in making the differential diagnosis of the hyperkinetic form of multiple sclerosis (MS) and hepatocerebral dystrophy (HCD), the authors performed a biochemical study characterizing liver function in 27 patients with MS attended by hyperkineses and in 14 patients with HCD. In addition to clinical symptoms, patients with the hyperkinetic form of MS, contrary to those with HCD, had biochemical parameters characterizing the differences of liver function in these diseases. These findings facilitate the differential diagnosis between the hyperkinetic form of MS and HCD.
